logo-loader
viewInstem PLC

Instem performing well; SEND platform stars

The company has developed software used by the life sciences industry to collate and transmit data

1532340324_FDA.jpg
SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration

Instem Plc (LON:INS), the developer of software used by the life sciences industry to collate and transmit data, said first-half trading was in line with market expectations.

The highlight was the performance of its SEND platform, with the value of contracts won thus far in 2018 exceeding the total for all of last year.

In all, it had 103 orders in the first six months from 50 different clients.

Instem said the contracted value of the SEND-related new business was up 190% year-on-year, while the pipeline continues to grow, driven by the US Food & Drug Administration’s investigational new drug rules.

SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Sending the right message

It said a further shift towards providing its software as a service (rather than making one-off sales), combined with “increasingly material recurring outsourced services revenue”, will see a continued improvement of earnings visibility.

Both its Provantis and Samarind products are accessible via the cloud.

Financially, Instem has a solid base with net cash of £3.7mln at June 30.

"The financial year has started well and we are confident further new business, the delivery of recent contract wins and strong operational management will ensure we meet our expectations for the full year," said chief executive Phil Reason.

Shares more than double in value

The shares, which have more than doubled in value in the year to date, rise 7% in morning trade to change hands for 315p. This values the business at £50mln.

In a note to clients, Progressive Equity said: “In our view, the overall tone of the update is optimistic and the outlook statement positive.”

Quick facts: Instem PLC

Price: 373 GBX

AIM:INS
Market: AIM
Market Cap: £61.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: CentralNic Group looks to acquire website provider Team...

Headlines from the Proactive UK newsroom. CentralNic Group (LON:CNIC) has confirmed advanced discussions are underway to acquire website provider Team Internet. The AIM-listed domain name specialist said further announcements will be made in due course. Life sciences group Instem (LON:INS)...

3 weeks, 5 days ago

2 min read